We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $138.68, marking a -0.27% move from the previous day. This change was narrower than the S&P 500's 0.43% loss on the day. Elsewhere, the Dow lost 0.5%, while the tech-heavy Nasdaq added 0.26%.
Heading into today, shares of the world's biggest maker of health care products had lost 2.06% over the past month, outpacing the Medical sector's loss of 4.49% and the S&P 500's loss of 4.68% in that time.
JNJ will be looking to display strength as it nears its next earnings release, which is expected to be January 22, 2019. In that report, analysts expect JNJ to post earnings of $1.95 per share. This would mark year-over-year growth of 12.07%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $20.11 billion, down 0.42% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.16 per share and revenue of $81.26 billion, which would represent changes of +11.78% and +6.29%, respectively, from the prior year.
Any recent changes to analyst estimates for JNJ should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.3% higher. JNJ is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, JNJ is currently trading at a Forward P/E ratio of 17.04. Its industry sports an average Forward P/E of 15.88, so we one might conclude that JNJ is trading at a premium comparatively.
Meanwhile, JNJ's PEG ratio is currently 2.17. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.05 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 47, putting it in the top 18% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $138.68, marking a -0.27% move from the previous day. This change was narrower than the S&P 500's 0.43% loss on the day. Elsewhere, the Dow lost 0.5%, while the tech-heavy Nasdaq added 0.26%.
Heading into today, shares of the world's biggest maker of health care products had lost 2.06% over the past month, outpacing the Medical sector's loss of 4.49% and the S&P 500's loss of 4.68% in that time.
JNJ will be looking to display strength as it nears its next earnings release, which is expected to be January 22, 2019. In that report, analysts expect JNJ to post earnings of $1.95 per share. This would mark year-over-year growth of 12.07%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $20.11 billion, down 0.42% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.16 per share and revenue of $81.26 billion, which would represent changes of +11.78% and +6.29%, respectively, from the prior year.
Any recent changes to analyst estimates for JNJ should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.3% higher. JNJ is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, JNJ is currently trading at a Forward P/E ratio of 17.04. Its industry sports an average Forward P/E of 15.88, so we one might conclude that JNJ is trading at a premium comparatively.
Meanwhile, JNJ's PEG ratio is currently 2.17. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.05 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 47, putting it in the top 18% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.